Movatterモバイル変換

[0]ホーム
URL:

AU2001249410A1 - Anti-c2/c2a inhibitors of complement activation - Google Patents

Anti-c2/c2a inhibitors of complement activation

Info

Publication number
AU2001249410A1
AU2001249410A1AU2001249410AAU4941001AAU2001249410A1AU 2001249410 A1AU2001249410 A1AU 2001249410A1AU 2001249410 AAU2001249410 AAU 2001249410AAU 4941001 AAU4941001 AAU 4941001AAU 2001249410 A1AU2001249410 A1AU 2001249410A1
Authority
AU
Australia
Prior art keywords
inhibitors
complement activation
antibody
complement
molecules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001249410A
Inventor
Michael Fung
Cecily Sun
William N. Sun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanox Inc
Original Assignee
Tanox Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanox IncfiledCriticalTanox Inc
Publication of AU2001249410A1publicationCriticalpatent/AU2001249410A1/en
Abandonedlegal-statusCriticalCurrent

Links

Classifications

Landscapes

Abstract

The invention relates to C2a inhibitors, which bind to C2a and block the functional activity of C2a in complement activation. The inhibitors include antibody molecules, as well as homologs, analogs and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab′)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody, which bound to C2a and blocked its ability to activate complement was generated and designated 175-62. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, under Accession Number PTA-1553.
AU2001249410A2000-03-232001-03-23Anti-c2/c2a inhibitors of complement activationAbandonedAU2001249410A1 (en)

Applications Claiming Priority (3)

Application NumberPriority DateFiling DateTitle
US19142900P2000-03-232000-03-23
US601914292000-03-23
PCT/US2001/009409WO2001070818A1 (en)2000-03-232001-03-23Anti-c2/c2a inhibitors of complement activation

Publications (1)

Publication NumberPublication Date
AU2001249410A1true AU2001249410A1 (en)2001-10-03

Family

ID=22705479

Family Applications (1)

Application NumberTitlePriority DateFiling Date
AU2001249410AAbandonedAU2001249410A1 (en)2000-03-232001-03-23Anti-c2/c2a inhibitors of complement activation

Country Status (9)

CountryLink
US (4)US6998468B2 (en)
EP (1)EP1265929B1 (en)
AT (1)ATE435873T1 (en)
AU (1)AU2001249410A1 (en)
DE (1)DE60139189D1 (en)
DK (1)DK1265929T3 (en)
ES (1)ES2329010T3 (en)
PT (1)PT1265929E (en)
WO (1)WO2001070818A1 (en)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
ES2329010T3 (en)2000-03-232009-11-20Genentech, Inc. ANTI-C2 / C2A INHIBITORS OF COMPLEMENT ACTIVATION.
ES2614274T3 (en)*2002-09-062017-05-30Alexion Pharmaceuticals, Inc. Asthma treatment procedure using antibodies against complement component C5
US20050271660A1 (en)*2002-09-062005-12-08Alexion Pharmaceuticals, Inc.Nebulization of monoclonal antibodies for treating pulmonary diseases
US9415102B2 (en)2002-09-062016-08-16Alexion Pharmaceuticals, Inc.High concentration formulations of anti-C5 antibodies
US7902338B2 (en)2003-07-312011-03-08Immunomedics, Inc.Anti-CD19 antibodies
US8501705B2 (en)*2003-09-112013-08-06The Board Of Regents Of The University Of Texas SystemMethods and materials for treating autoimmune and/or complement mediated diseases and conditions
CN107929731A (en)2005-11-042018-04-20健泰科生物技术公司Utilize complement pathway inhibitors to treat ocular diseases
US20110014270A1 (en)*2006-03-272011-01-20The Regents Of The University Of ColoradoPrevention and treatment of ischemia-reperfusion injury and related conditions
RU2474589C9 (en)*2006-11-022019-08-15Дженентек, Инк.Humanised anti-factor d antibodies and use thereof
DK2148691T3 (en)2007-02-052015-08-17Apellis Pharmaceuticals IncCompstatinanaloger for use in the treatment of inflammatory states of the respiratory system
CR20170001A (en)2008-04-282017-08-10Genentech Inc ANTI FACTOR D HUMANIZED ANTIBODIES
PL2396036T3 (en)2009-02-132017-12-29Immunomedics, Inc.Immunoconjugates with an intracellularly-cleavable linkage
EP2478110B1 (en)2009-09-162016-01-06Immunomedics, Inc.Class i anti-cea antibodies and uses thereof
CA2782194C (en)2009-12-022018-01-16Immunomedics, Inc.Combination of radiolabelled antibodies (rait) and antibody-drug conjugates (adc) for treatment of pancreatic cancer
AU2012250924B2 (en)2011-05-022017-05-25Immunomedics, Inc.Ultrafiltration concentration of allotype selected antibodies for small-volume administration
CA2840270C (en)2011-06-222023-09-26Apellis Pharmaceuticals, Inc.Methods of treating chronic disorders with complement inhibitors
CN109513003A (en)2012-08-142019-03-26Ibc药品公司T- cell for treating disease redirects bispecific antibody
EP2912065A4 (en)2012-10-252016-10-19True North Therapeutics Inc ANTIBODY ANTIBODY ANTIBODIES AND USES THEREOF
CA2889197A1 (en)2012-11-022014-05-08True North Therapeutics, Inc.Anti-complement c1s antibodies and uses thereof
CN118001422A (en)2012-12-132024-05-10免疫医疗公司Dosage of immunoconjugates of antibodies with SN-38 with improved efficacy and reduced toxicity
PL2999714T3 (en)*2013-05-232020-10-19Broteio Pharma B.V.Binding molecules that bind human complement factor c2 and uses thereof
KR20160042438A (en)2013-08-122016-04-19제넨테크, 인크.Compositions and method for treating complement-associated conditions
US10238700B2 (en)2014-01-022019-03-26Genelux CorporationOncolytic virus adjunct therapy with agents that increase virus infectivity
CN106132436B (en)2014-02-212021-06-15Ibc药品公司 Disease therapy by inducing an immune response to TROP-2 expressing cells
US9139649B2 (en)2014-02-252015-09-22Immunomedics, Inc.Humanized anti-CD22 antibody
MA39934A (en)2014-05-012017-03-08Hoffmann La RocheAnti-factor d antibody variants and uses thereof
WO2015200260A1 (en)2014-06-242015-12-30Immunomedics, Inc.Anti-histone therapy for vascular necrosis in severe glomerulonephritis
PL3204018T3 (en)2014-10-072022-01-03Immunomedics, Inc.Neoadjuvant use of antibody-drug conjugates
KR20170080604A (en)2014-11-102017-07-10제넨테크, 인크.Anti-interleukin-33 antibodies and uses thereof
MX389703B (en)2015-04-062025-03-20Bioverativ Usa Inc HUMANIZED ANTI-C1S ANTIBODIES AND METHODS OF USING THEM.
CN107428837A (en)2015-04-222017-12-01免疫医疗公司Circulate separation, detection, diagnosis and/or the identification of the positive cancer cells of TROP 2
CN107735104B (en)2015-06-252022-05-03免疫医疗公司 Combining anti-HLA-DR or anti-TROP-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors, or phosphoinositide 3-kinase inhibitors significantly improves cancer outcomes
PL3316885T3 (en)2015-07-012021-12-06Immunomedics, Inc. ANTIBODY-SN-38 IMMUNOCONIUGATS WITH CL2A LINKER
TW201730211A (en)2015-10-302017-09-01建南德克公司Anti-Factor D antibodies and conjugates
CN108472382A (en)2015-10-302018-08-31豪夫迈·罗氏有限公司Anti- factor D antibody variants conjugate and application thereof
CN108934169A (en)2016-01-202018-12-04维特里萨医疗公司Composition and method for inhibiting factor D
AR110677A1 (en)2016-10-122019-04-24Bioverativ Usa Inc ANTI-C1S ANTIBODIES AND METHODS TO USE THEM
WO2018136827A1 (en)2017-01-202018-07-26Vitrisa Therapeutics, Inc.Stem-loop compositions and methods for inhibiting factor d
LT3893924T (en)2018-12-132024-10-10argenx BVAntibodies to human complement factor c2b and methods of use
WO2021026609A1 (en)*2019-08-122021-02-18CSL Innovation Pty LtdComplement c2 binding proteins and uses thereof
WO2021067526A1 (en)2019-10-022021-04-08Alexion Pharmaceuticals, Inc.Complement inhibitors for treating drug-induced complement-mediated response
EP4118114A1 (en)2020-03-132023-01-18Genentech, Inc.Anti-interleukin-33 antibodies and uses thereof
EP4150338A1 (en)2020-05-152023-03-22Alexion Pharmaceuticals, Inc.Method of using extracellular vesicles to detect complement activation, and uses thereof to assess and/or monitor treatment of a complement-mediated disease
US20250073349A1 (en)2021-05-102025-03-06Kawasaki Institute Of Industrial PromotionAntibody having reduced binding affinity for antigen
EP4469475A1 (en)*2022-01-292024-12-04Kira Pharmaceuticals (Suzhou) Ltd.Anti-c2 antibodies and uses thereof
WO2024238422A1 (en)2023-05-122024-11-21Alexion Pharmaceuticals, Inc.Use of a panel of lectins for detection of complement biomarkers in urine extracellular vesicles
WO2024238421A1 (en)2023-05-122024-11-21Alexion Pharmaceuticals, Inc.Use of biomarkers for the identification and treatment of complement-mediated disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US5225539A (en)*1986-03-271993-07-06Medical Research CouncilRecombinant altered antibodies and methods of making altered antibodies
US4946778A (en)*1987-09-211990-08-07Genex CorporationSingle polypeptide chain binding molecules
US5530101A (en)*1988-12-281996-06-25Protein Design Labs, Inc.Humanized immunoglobulins
US5861156A (en)*1993-01-081999-01-19Creative BiomoleculesMethods of delivering agents to target cells
CA2198706C (en)1994-09-232008-07-08Yi WangMethods for the treatment of inflammatory joint disease
ES2329010T3 (en)*2000-03-232009-11-20Genentech, Inc. ANTI-C2 / C2A INHIBITORS OF COMPLEMENT ACTIVATION.

Also Published As

Publication numberPublication date
US20010026928A1 (en)2001-10-04
EP1265929A1 (en)2002-12-18
US7927592B2 (en)2011-04-19
US6998468B2 (en)2006-02-14
EP1265929B1 (en)2009-07-08
US8911735B2 (en)2014-12-16
ES2329010T3 (en)2009-11-20
ATE435873T1 (en)2009-07-15
PT1265929E (en)2009-10-15
WO2001070818A1 (en)2001-09-27
DE60139189D1 (en)2009-08-20
US20110165169A1 (en)2011-07-07
DK1265929T3 (en)2009-11-16
US20050196394A1 (en)2005-09-08
WO2001070818A8 (en)2001-12-06
US20120251549A1 (en)2012-10-04
US8221756B2 (en)2012-07-17

Similar Documents

PublicationPublication DateTitle
AU2001249410A1 (en)Anti-c2/c2a inhibitors of complement activation
EP1054693B8 (en)Inhibitors of complement activation
AU2001296594A1 (en)Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection
KR960704576A (en) Antibodies to CD40
WO2007062245A3 (en)Human monoclonal antibody human cd134 (ox40) and methods of making and using same
TW200722518A (en)Sc(fv)2 structural isomers
KR102346988B1 (en) anti-B7-H4 antibody
AR085874A2 (en) A MONOCLONAL ANTIBODY OR A FRAGMENT OF THE SAME THAT JOINS AN ANTIGEN
NZ599683A (en)Anti-ilt7 antibody
NZ597067A (en)Monoclonal antibodies expressed by ATCC PTA-4621 for the treatment of cancer
NZ611387A (en)Selected antibodies binding to anionic phospholipids and aminophospholipids and their use in treatment
MA29374B1 (en) ANTI-CCR5 ANTIBODIES AND USES THEREOF
NZ623319A (en)Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
HRP20090527T1 (en) IMMUNOGLOBULINS FOR NEUTRALIZATION OF THE FOOT, INTENDED FOR THE TREATMENT OF NEUROLOGICAL DISEASES
UA89017C2 (en)HUMAN ANTIBODY THAT SPECIFICALLY BINDS TO hTNFSF13B
EA200870072A1 (en) ANTI INFLAMMATORY dAb
WO2004005350A3 (en)Mutant fab fragments of the chimeric 13b8.2 anti-cd4 antibody and uses thereof
MX2007000103A (en)Universal antibody libraries.
WO2002074251A3 (en)Monoclonal antibody therapy for pancreas cancer
Maderspach et al.A Monoclonal Antibody Recognizing K‐but Not γ‐and δ‐Opioid Receptors
EP1468022A4 (en)Novel monoclonal antibody and nematode larval antigens
AU2001270518A1 (en)Hypha-specific factors from candida albicans
TH2001001390A (en) Anti-CD3 Epsilon, a new antibody
UA90242C2 (en)MONOCLONAL ANTIBODY WHICH SPECIFICALLY BINDS TO αVβ6
SE9501302D0 (en) Antibodies for use in cancer therapy and diagnosis
[8]ページ先頭
©2009-2025 Movatter.jp